Devenir des patients BPCO traités par ventilation non invasive prolongée à domicile
The use of domiciliary non-invasive positive pressure ventilation (NIPPV) is still controversial in stable hypercapnic COPD.Methods
Records of COPD patients who received home NIPPV from 1990 to 2002 either following an acute exacerbation or because of stable hypercapnia were retrospectively reviewed.ResultsThirty-seven patients receiving long term oxygen therapy for 50 ± 47 months were included. At inclusion, their mean ± SD: FEV1 was 27 ± 9% predicted, inspiratory capacity was 45 ± 14% predicted, PaO2 breathing room air was 50 ± 10 mm Hg, PaCO2 breathing room air = 53 ± 8 mm Hg, PaCO2 with oxygen was 60 ± 9 mm Hg. Median survival with NIPPV was 41 months. The 1-year, 3-year and 5-year survival rates with NIPPV were 92%, 62% and 24% respectively. Twelve months after onset of home NIPPV, PaCO2 breathing room air and with oxygen were significantly lower (47 ± 8 mm Hg, p = 0.028 and 53 ± 8 mm Hg, p = 0.005, respectively), inspiratory capacity was significantly improved (54 ± 18% predicted, p = 0.033).Conclusion
This study suggests that home NIPPV allows a las-ting physiological stabilization in selected COPD patients, parti-cularly those with an advanced disease, by reducing hypercapnia and improving Inspiratory Capacity.